Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials

Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.

Authors

Institutions

Publication Details

Journal
Neurology
Published
2025-12-09
DOI
https://doi.org/10.1212/wnl.0000000000214441
Citations
3
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
3.49
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials

Hyun Woong Roh, Wyllians Vendramini Borelli, Dana Tudorascu, Helmet T. Karim et al.
3 citations
Neurology
Alzheimer's disease research and treatments
3.49
article

Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials

Hyun Woong Roh, Wyllians Vendramini Borelli, Dana Tudorascu, Helmet T. Karim, Tharick Ali Pascoal, João Pedro Ferrari‐Souza, Marina Scop Medeiros, Cynthia Felix, Tobey J. Betthauser, Guilherme Povala, Douglas Teixeira Leffa, Eduardo Rigon Zimmer, Rachael Wilson, Rebecca L. Koscik, Chang Hyung Hong, Carolina Soares, Sang Joon Son, Guilherme Bauer‐Negrini, Pâmela C.L. Ferreira, Emma Patrice Ruppert, Beth E. Snitz, Thomas K. Karikari, Bruna Bellaver, Firoza Zubeida Lussier, Cristiano Schaffer Aguzzoli, Francieli Rohden, Sterling C. Johnson, Riddhi Patira, Bradley T. Christian
article en
3 citations

Abstract

Our findings support that changes in plasma p-tau217 represent a robust endpoint for clinical trials targeting CU or CI individuals with Aβ pathology.

NeurologyVol. 106(1)
Universidade Federal do Rio Grande do Sul (BR), University of Wisconsin–Madison (US), University of Pittsburgh (US), Instituto do Cérebro (BR), Hospital Moinhos de Vento (BR), Intelligent Systems Research (United States) (US), Wisconsin Division of Public Health (US), Global Brain Health Institute (US), Pontifícia Universidade Católica do Rio Grande do Sul (BR), McGill University (CA), Ajou University (KR)
Openalex Percentile: Top 7%
Alzheimer's disease research and treatments
3.49
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.